Baruch P, Brion S, Broussolle P, Gayral L F, Ropert R, Volmat R, Porot M
Service de Psychiatrie (Adultes), Hôpital de la Salpêtrière, Paris.
Encephale. 1989 Sep-Oct;15(5):449-55.
The results of a one-year, open multicenter trial of perphenazine enanthate, a sustained-release neuroleptic drug, are reported. 240 patients (62% suffering from schizophrenia) were included in the study and 144 were followed during the 12-month period. The usual adverse reactions associated with sustained-release neuroleptic drugs were observed. Total and partial BPRS ratings showed that improvement (expressed as a percentage) after 12 months' treatment was similar for systematized chronic delusions, paranoid schizophrenia and hebephrenia. However, the onset of therapeutic activity was different in these three groups of patients. Maximum therapeutic activity, as defined by the BPRS rating, was obtained within 4 months in chronic delusions whereas schizophrenia improved more progressively. Such patients therefore require prolonged treatment before the therapeutic activity of a sustained-release neuroleptic drug can be assessed.
本文报告了长效抗精神病药物奋乃静庚酸酯为期一年的开放性多中心试验结果。该研究纳入了240名患者（62%患有精神分裂症），其中144名患者在12个月期间接受了随访。观察到了与长效抗精神病药物相关的常见不良反应。总体和部分简明精神病评定量表（BPRS）评分显示，经过12个月治疗后，系统性慢性妄想症、偏执型精神分裂症和青春型精神分裂症的改善情况（以百分比表示）相似。然而，这三组患者的治疗活动起效时间不同。根据BPRS评分定义，慢性妄想症患者在4个月内达到最大治疗效果，而精神分裂症患者的改善则更为渐进。因此，在评估长效抗精神病药物的治疗活性之前，这类患者需要接受较长时间的治疗。
